Supernus Pharmaceuticals, Inc.
SUPN
$44.12
-$0.58-1.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 16.11% | 10.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.11% | 10.43% | |||
| Cost of Revenue | 187.22% | 6.75% | |||
| Gross Profit | -3.27% | 10.86% | |||
| SG&A Expenses | 17.37% | 0.22% | |||
| Depreciation & Amortization | 16.84% | 5.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.00% | -1.60% | |||
| Operating Income | -23.93% | 259.25% | |||
| Income Before Tax | -447.68% | 385.87% | |||
| Income Tax Expenses | -120.19% | -197.23% | |||
| Earnings from Continuing Operations | -300.53% | 290.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -300.53% | 290.23% | |||
| EBIT | -23.93% | 259.25% | |||
| EBITDA | 2.41% | 142.77% | |||
| EPS Basic | -298.66% | 289.70% | |||
| Normalized Basic EPS | -32.04% | 706.94% | |||
| EPS Diluted | -300.00% | 288.95% | |||
| Normalized Diluted EPS | -31.29% | 700.35% | |||
| Average Basic Shares Outstanding | 0.94% | 0.29% | |||
| Average Diluted Shares Outstanding | -0.16% | 1.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||